1. Home
  2. RNW vs PTGX Comparison

RNW vs PTGX Comparison

Compare RNW & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNW
  • PTGX
  • Stock Information
  • Founded
  • RNW 2011
  • PTGX 2006
  • Country
  • RNW United Kingdom
  • PTGX United States
  • Employees
  • RNW N/A
  • PTGX N/A
  • Industry
  • RNW Electric Utilities: Central
  • PTGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNW Utilities
  • PTGX Health Care
  • Exchange
  • RNW Nasdaq
  • PTGX Nasdaq
  • Market Cap
  • RNW 2.7B
  • PTGX 3.7B
  • IPO Year
  • RNW N/A
  • PTGX 2016
  • Fundamental
  • Price
  • RNW $7.73
  • PTGX $59.61
  • Analyst Decision
  • RNW Strong Buy
  • PTGX Strong Buy
  • Analyst Count
  • RNW 1
  • PTGX 9
  • Target Price
  • RNW $7.50
  • PTGX $70.44
  • AVG Volume (30 Days)
  • RNW 720.4K
  • PTGX 925.0K
  • Earning Date
  • RNW 08-13-2025
  • PTGX 11-06-2025
  • Dividend Yield
  • RNW N/A
  • PTGX N/A
  • EPS Growth
  • RNW 1063.89
  • PTGX N/A
  • EPS
  • RNW 0.28
  • PTGX 0.80
  • Revenue
  • RNW $1,320,468,726.00
  • PTGX $209,180,000.00
  • Revenue This Year
  • RNW N/A
  • PTGX N/A
  • Revenue Next Year
  • RNW $16.12
  • PTGX $248.17
  • P/E Ratio
  • RNW $27.51
  • PTGX $73.55
  • Revenue Growth
  • RNW 37.94
  • PTGX N/A
  • 52 Week Low
  • RNW $5.15
  • PTGX $33.31
  • 52 Week High
  • RNW $7.89
  • PTGX $61.89
  • Technical
  • Relative Strength Index (RSI)
  • RNW 54.88
  • PTGX 56.56
  • Support Level
  • RNW $7.64
  • PTGX $57.90
  • Resistance Level
  • RNW $7.76
  • PTGX $61.34
  • Average True Range (ATR)
  • RNW 0.12
  • PTGX 2.36
  • MACD
  • RNW -0.00
  • PTGX -0.07
  • Stochastic Oscillator
  • RNW 76.82
  • PTGX 74.69

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: